ENTRESTO® has proven to be an ESSENTIAL treatment in HFrEF—with over 8 years of real-world experience1-5
As the first and only ARNi, ENTRESTO has paved the way in patients with LVEF ≤60%1-4,6-8:
*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1
†PROVE-HF was a single-arm, open-label study.
‡PARAGLIDE-HF defined HFmrEF and HFpEF as patients with LVEF >40%. LVEF is a variable measure that can change over time, and the normal range differs according to patient characteristics and method of assessment.
§Worsening HF event was defined as an HF hospitalization, emergency department visit, or out-of-hospital urgent HF visit, all requiring IV diuretics.
| 2022 AHA/ACC/HFSA HF Guideline strongly recommends ENTRESTO for HFrEF and has expanded its recognition in select HFmrEF and HFpEF patients with LVEF on the lower end of the spectrum5‖ | ||
| HFrEF LVEF ≤40% | HFmrEF LVEF 41% to 49% | HFpEF LVEF ≥50% |
| ~80% of patients with HF have LVEF ≤60% and may be appropriate for ENTRESTO5,7 | ||
| The 2023 ACC ECDP for HFpEF favors the use of ENTRESTO instead of an ARB for HFpEF patients with LVEF <55% to 60%, unless not feasible due to contraindication, cost, or intolerance.9 | ||
‖In the 2022 HF Guideline, ENTRESTO is recommended as a first-line treatment and to replace well-tolerated ACEi/ARB in patients with NYHA Class II–III HFrEF (Class 1 recommendation). ENTRESTO was also included as a treatment option for HFmrEF (LVEF 41%–49%) and select patients with HFpEF (LVEF ≥50%), particularly for patients with LVEF on the lower end of the spectrum (Class 2b recommendation).
